Not-for-profit and public healthcare - US

2018 outlook changed to negative due to reimbursement and expense pressures

Our negative outlook indicates our expectations for the fundamental credit conditions driving the not-for-profit and public healthcare sector over the next 12-18 months. We revised the US not-for-profit and public healthcare outlook to negative from stable based on our projections that operating cash flow will contract by 2%-4% over the next 12-18 months. Revenue growth is under pressure because of very low reimbursement rate increases, an ongoing rise in government payors and a continued shift to high deductible plans. We expect rapid expense growth to outpace revenue growth with high labor costs, nursing shortages and rising bad debt.

» Operating cash flow will contract by 2%-4% in 2018. Operating pressures are accelerating at hospitals because of low revenue growth and untamed expense growth.

» Low reimbursement rates drive slowed revenue growth despite consistent volumes. Hospitals are unable to translate volume increases into stronger revenue growth because of below inflationary growth of reimbursement rates and rising bad debt.

» Expense pressures further compress margins. Nursing shortages, continued physician and medical specialist hiring, as well as technological investments are accelerating expense growth. Bad debt will grow in 2018 with high deductibles, rising copays, and contracting exchange enrollment because of changes in federal marketing.

» Federal policy will have marginal near term direct impact, but continued uncertainty is credit negative. Federal healthcare policy actions to date will have a negative effect on a small segment of hospitals that we rate. Uncertainty around the Affordable Care Act (ACA) makes it very difficult for hospitals to effectively plan and model long-term strategies. Recent federal tax proposals will also contribute to rising costs for hospitals.

» Heightened operating pressure will drive additional consolidations. We expect that mergers and acquisitions will continue at a rapid pace as smaller and more rural hospitals struggle for financial stability.

» What could change the outlook. Resumed operating cash flow growth of 0%-4% over a 12-18 month period, after accounting for healthcare inflation, could drive a change to stable. A positive outlook could result from expectations of accelerated operating cash flow growth of more than 4% after inflation. Long-term resolution of federal policy or positive regulatory changes could result in a change in outlook.
Operating cash flow will contract by 2%-4% in 2018

Operating cash flow declined at a more rapid pace than expected in 2017, and we expect continued contraction of 2%-4% through 2018. The cash flow spike from insurance expansion under the ACA in 2014 and 2015 has largely worn off, but cash flow has not stabilized as we had expected because of a low revenue/high expense growth environment (see Exhibit 1). Top-line revenue growth is still strong, but diminished from previous years because of constrained reimbursement rate increases. Margins and operating cash flow will compress as expenses and bad debt continue to rise.

Exhibit 1
Projections for contracting operating cash flow underscore negative outlook

Source: Moody’s Investors Service

Low reimbursement rates drive slowed revenue growth despite consistent volumes

Revenue growth is slowing, and we expect it to remain slightly above medical inflation for hospitals and systems that we rate. Growth will be largely based on expansion strategies founded upon continued acquisitions, including outpatient sites and physician practices, rather than same store revenue growth. This projected level of growth would represent a steady three-year decline in revenue growth off a recent peak in 2015, and the slowest revenue growth since 2013.

Hospitals have not been able to translate relatively stable volumes into stable revenue growth because of lower reimbursement rate increases across all insurance providers (see Exhibit 2). In 2018, inpatient volume growth will remain low as care continues to shift to less costly outpatient services, and patients defer or make alternative choices because of higher deductibles and copays. A small rise in the percentage of uninsured population (see federal policy section) will also contribute to lower inpatient volumes.

Because our outlooks represent our forward-looking view on credit conditions that factor into our ratings, a negative (positive) outlook suggests that negative (positive) rating actions are more likely on average. However, the outlook does not represent a sum of upgrades, downgrades or ratings under review, or an average of the rating outlooks of issuers in the country or sector, but rather our assessment of the main direction of credit fundamentals within the country, region or sector.
Growth of governmental payors will dampen revenue growth for the foreseeable future due to a rapidly aging US population and low reimbursement rates. Most reimbursement rates will hover below medical inflation, which declined to a low 1.6% in September 2017. Governmental payors, including Medicare and Medicaid, represent 61% of gross patient revenue in 2016 (see Exhibit 3). Medicare, the majority revenue source, continues its multi-year trend of very low reimbursement rate increases, with inpatient admission rates growing by just 1.3% in 2018. Medicare growth has been low, in the 1%-2% range over the last several years, and is not expected to grow substantially in the near term. Medicaid reimbursement rates will vary by state, but with burgeoning Medicaid expenses, many states have begun to make cuts or are delaying payments.

We estimate that commercial insurers, which represent about one-third of gross patient revenue, will raise rates at about inflation and lower insurance coverage. Many are also cutting services or increasing denials to control costs, often squeezing hospitals’ higher margin service lines. For example, Anthem, Inc. (Baa2 stable, P-2) recently announced that it will no longer reimburse for certain MRI services at hospital-based centers due to high costs. Insurers and employees continue to shift costs to the patient through growth in high-deductible plans, which increases hospitals’ copay collection burdens and will likely increase bad debt.
Rapid expense growth and rising bad debt will further compress margins

Expense growth will remain higher than revenue growth, a key driver of operating cash flow contraction. Median expense growth is usually at around 5%-6%, but grew to recent peak of 7.2% in fiscal 2016. The key driver of expense growth through 2018 will continue to be high labor costs. Nursing shortages remain acute — especially in urban centers, medical specialist fees are rising and hospitals continue to hire additional physicians. Recent upgrades of technological platforms and electronic medical records systems are increasingly requiring additional information technology staff as hospitals adapt processes and train staff on new systems. We expect supply costs to continue on a normal growth trend, with the recent spike in pharmaceutical costs subsiding over the near term. Pension costs will continue to grow for private hospitals with the federal government’s pension guarantee agency (Pension Benefit Guaranty Corporation, or PBGC) premium step ups through 2019.

Rising costs will disproportionately affect small independent hospitals (less than $400 million in revenues) which represent 23% of the hospitals that we rate. These hospitals are at a disadvantage in negotiating with vendors as well as with attracting physicians. They have fewer financial resources and therefore it is difficult to match the salaries and benefits offered by larger urban systems.

Academic medical centers will continue to have higher expense growth rates than other not-for-profit hospitals, offset by stronger revenue growth. Some factors contributing to elevated expenses at AMCs include: high infrastructure investments to maintain strong research, elevated recruiting costs to attract faculty and medical specialists, and financial transfers to associated medical schools.

Rising bad debt adds further pressure

We expect bad debt to grow 6%-7% in 2018, up from 5% in 2017, and slightly higher than revenue growth adding to margin pressures (see Exhibit 4). Reduced federal marketing and promotion of the ACA’s exchange marketplaces will marginally increase the number of uninsured people, causing bad debt to grow at a somewhat faster pace than last year. Rising copays and use of high deductible plans will increase bad debt for both expansion and non expansion states.

Federal policy to date has marginal direct effect, but continued uncertainty and recent tax proposals are credit negative

The Trump administration has issued several executive orders that perpetuate the uncertainty around longer term stability of the individual marketplaces for health insurance, known as the exchanges. The recent actions would be largely credit negative for not-for-profit hospitals, but the immediate effect will be muted because most insurance premium rates are in place through 2018, and the populations affected by these orders are relatively small.

However, although we anticipate that any changes to policy will be rolled out slowly, the prolonged uncertainty around the future of federal policy creates a difficult environment for long-term planning.

The recent executive orders, CMS rulings and legislative proposals are largely credit negative, but with varying effect.
» **Repeal of individual mandate**: A repeal of the individual mandate has been included in tax reform legislation. A repeal would cause some individuals to forgo insurance; a larger uninsured population would raise uncompensated care costs for hospitals, which is credit negative.

» **Association health plans and expansion of short-term health plans**: The order to consider proposing new rules or revising existing ones to ease regulations on association health plans and expand the definition of short-term health insurance, which is not subject to ACA rules, will not have an immediate effect. Any changes developed would take several months to draft and enact. However, if introduced, the 10 million to 12 million unsubsidized individuals now in the ACA marketplaces or on the exchange could be swayed to lower cost, less comprehensive health insurance plans. This would have a negative impact on hospitals, driving up uncompensated care costs as fewer services are covered by non-ACA compliant plans.

» **ACA advertising and promotion**: The shorter enrollment period and greatly reduced marketing budget for the ACA insurance exchanges will result in a modest uptick of uninsured in 2018. A larger uninsured population would raise uncompensated care costs for hospitals, which is credit negative.

» **Cost-sharing reduction (CSR)**: The administration’s order would end the federal government’s about $7 billion of CSR reimbursement payments to insurers that provide ACA-mandated subsidies of out-of-pocket costs and deductibles for certain low-income exchange enrollees. About 80% of people on the exchanges are subsidized. This change would primarily affect the 20% who are not subsidized, leading to higher insurance premiums, which is credit negative for not-for-profit hospitals because individuals may chose to discontinue coverage.

» **Disproportionate Share Hospital (DSH) program**: The Medicaid DSH program was cut by $2 billion, effective October 1, 2017, with additional cuts scheduled to take place each year over the next eight years. Medicare DSH payments are rising a very low 0.7%. The greatest impact will be felt largely by safety-net hospitals whose uncompensated care will increase.

» **Children's Health Insurance program (CHIP)**: Potential discontinuation of CHIP would impact about 9 million children and mothers. The largest impact would be to children’s hospitals, which tend to have very strong fundraising and balance sheets to help offset near-term revenue loss.

» **Reductions to 340b drug program**: The recently enacted 30% reduction to Medicare Part B drug reimbursement to 340b hospitals will not, on its own, have a material effect on most not-for-profit hospitals. However, the reductions will be a significant challenge for hospitals with low financial flexibility to absorb small revenue changes. We estimate that total 340b savings for all covered entities was about $6.9 billion in 2016.

» **Tax proposals**: Recent tax proposals from the House and Senate would be credit negative for not-for-profit healthcare. If enacted, the changes would drive up the cost of capital, contributing to greater merger and acquisition activity. Smaller hospitals would be less able to afford higher interest rate costs in the taxable market, and in order to meet capital needs, would likely look to find partners.

**Heightened operating pressure will accelerate consolidation**

Mergers, acquisitions and strategic alliances will continue at a rapid pace, especially for rural or community hospitals and in markets with Medicaid cuts or declining commercial insurers. Healthcare continues to be a crowded and highly regulated market, which heightens competition and revenue pressure. Operating scale and efficiency have become increasingly important as hospitals look for ways to control expenses in light of low reimbursement rates and a continued shift to outpatient services from higher margin inpatient services. Large hospital systems and high-acuity academic medical centers that are associated with strong universities continue to fare better because of economies of scale and brand recognition. Rural hospitals are struggling and are likely to be increasingly acquired by major systems in nearby urban hubs.

Recent consolidation among physician groups and the reentry of physician management companies that are acquiring large independent physician groups will also heighten competitive pressures. As part of a larger organization, these physician companies have greater negotiating leverage with payors and hospitals for contracted rates. Optum, a division of United Healthcare (A3 stable, P-2) has been buying physician groups and ambulatory centers across the US and in early 2017, purchased Surgical Care Affiliates, the largest operator of free-standing surgical centers in the US.
What could change the outlook

Our outlook could return to stable if the operating environment improves, bringing stronger revenue growth and stabilization of expense growth. Resolution of federal healthcare policy that leads to more long-term funding certainty could also result in a stable outlook. We would consider changing the outlook to stable if we were to expect resumed operating cash flow growth of 0%-4%.

We would consider changing our outlook to positive with projection of sustained strong operating cash flow growth of above 4%, robust economic expansion, and expectations of material improvement of reimbursement rates or federal policy changes that improve reimbursements.

Moody’s related publications

Outlooks:

» Cross-Sector - Global: 2018 Outlook: Credit conditions improve as healthy economic growth moderates financial stability and political risks, November 2017


» Sovereigns – Global: 2018 outlook stable as healthy growth tempers high debt, geopolitical tensions, November 2017

Sector In-Depths:

» Cross-Sector - US - FAQ on credit implications of recent executive actions on healthcare

» Not-for-profit and public healthcare, Pharmaceuticals - US - Drug price increases abate, but potential 340B change would hurt hospital margins

» Not-for-profit and public healthcare - US Medians - Key financial metrics underperform as pressures mount

» State Government - US - Medicaid Pressures State Budgets With or Without Federal Policy Changes

To access any of these reports, click on the entry above. Note that these references are current as of the date of publication of this report and that more recent reports may be available. All research may not be available to all clients.
Endnotes

1. US Bureau of Labor Statistics — CPI-All Urban Consumers
2. CMS finalizes 2018 payment and policy updates for Medicare hospital admissions, Centers for Medicare & Medicaid Services, August 2, 2017
MJKK and MSFJ also maintain policies and procedures to address Japanese regulatory requirements. 

ranging from JPY200,000 to approximately JPY350,000,000.

stock rated by MJKK or MSFJ (as applicable) have, prior to assignment of any rating, agreed to pay to MJKK or MSFJ (as applicable) for appraisal and rating services rendered by it fees ranging from $1,500 to approximately $2,500,000. MCO and MIS also maintain policies and procedures to address the independence of MIS’s ratings and rating processes. Information regarding certain affiliations that may exist between directors of MCO and rated entities, and between entities that hold ratings from MIS and have also publicly reported to the SEC an ownership interest in MCO of more than 5%, is posted annually at www.moodys.com under the heading “Investor Relations — Corporate Governance — Director and Shareholder Affiliation Policy.”

Additional terms for Australia only: Any publication into this document is pursuant to the Australian Financial Services License of MOODY’S affiliate, Moody’s Investors Service Pty Limited ABN 61 003 399 657AFSL 336969 and/or Moody’s Analytics Australia Pty Limited ABN 94 105 136 972 AFSL 383569 (as applicable). This document is intended to be provided only to “wholesale clients” within the meaning of section 761G of the Corporations Act 2001. By continuing to access this document from within Australia, you represent to MOODY’S that you are, or are accessing the document as a representative of, a “wholesale client” and that neither you nor the entity you represent will directly or indirectly disseminate this document or its contents to “retail clients” within the meaning of section 761G of the Corporations Act 2001. MOODY’S credit rating is an opinion as to the creditworthiness of a debt obligation of the issuer, not on the equity securities of the issuer or any form of security that is available to retail investors. It would be reckless and inappropriate for retail investors to use MOODY’S credit ratings or publications when making an investment decision. If in doubt you should contact your financial or other professional adviser.

Additional terms for Japan only: Moody’s Japan K.K. (“MJJK”) is a wholly-owned credit rating agency subsidiary of Moody’s Group Japan K.K., which is wholly-owned by Moody’s Overseas Holdings Inc., a wholly-owned subsidiary of MCO. Moody’s K.K. (“MSFJ”) is a wholly-owned credit rating agency subsidiary of MJJK. MSFJ is not a NRSRO. Therefore, credit ratings assigned by MSFJ are Non-NRSRO Credit Ratings. Non-NRSRO Credit Ratings are assigned by an entity that is not a NRSRO and, consequently, the rated obligation will not qualify for certain types of treatment under U.S. laws. MJJK and MSFJ are credit rating agencies registered with the Japan Financial Services Agency and their registration numbers are FSA Commissioner (Ratings) No. 2 and 3 respectively. MJJK or MSFJ (as applicable) hereby disclose that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by Moody’s Investors Service, Inc. (as applicable) for appraisal and rating services rendered by it fees ranging from JP¥200,000 to approximately JP¥350,000,000. MJJK and MSFJ also maintain policies and procedures to address Japanese regulatory requirements.

© 2017 Moody’s Corporation, Moody’s Investors Service, Inc., Moody’s Analytics, Inc. and/or their licensors and affiliates (collectively, “MOODY’S”). All rights reserved. CREDIT RATINGS ISSUED BY MOODY’S INVESTORS SERVICE, INC. AND ITS RATINGS AFFILIATES (“MIS”) ARE MOODY’S CURRENT OPINIONS OF THE RELATIVE FUTURE CREDIT RISK OF ENTITIES, CREDIT COMMITMENTS, OR DEBT OR DEBT-LIKE SECURITIES, AND MOODY’S PUBLICATIONS MAY INCLUDE MOODY’S CURRENT OPINIONS OF THE RELATIVE FUTURE CREDIT RISK OF ENTITIES, CREDIT COMMITMENTS, OR DEBT OR DEBT-LIKE SECURITIES. MOODY’S DEFINES CREDIT RISK AS THE RISK THAT AN ENTITY MAY NOT MEET ITS CONTRACTUAL, FINANCIAL OBLIGATIONS AS THEY COME DUE AND ANY ESTIMATED FINANCIAL LOSS IN THE EVENT OF DEFAULT. CREDIT RATINGS DO NOT ADDRESS ANY OTHER RISK, INCLUDING BUT NOT LIMITED TO: LIQUIDITY RISK, MARKET VALUE RISK, OR PRICE VOLATILITY. CREDIT RATINGS AND MOODY’S OPINIONS INCLUDED IN MOODY’S PUBLICATIONS ARE NOT STATEMENTS OF CURRENT OR HISTORICAL FACT. MOODY’S PUBLICATIONS MAY ALSO INCLUDE QUANTITATIVE MODEL-BASED ESTIMATES OF CREDIT RISK AND RELATED OPINIONS OR COMMENTARY PUBLISHED BY MOODY’S ANALYTICS, INC. CREDIT RATINGS AND MOODY’S PUBLICATIONS DO NOT CONSTITUTE OR PROVIDE INVESTMENT OR FINANCIAL ADVICE, AND CREDIT RATINGS AND MOODY’S PUBLICATIONS ARE NOT AND DO NOT PROVIDE RECOMMENDATIONS TO PURCHASE, SELL, OR HOLD PARTICULAR SECURITIES. NEITHER CREDIT RATINGS NOR MOODY’S PUBLICATIONS COMMENT ON THE SUITABILITY OF AN INVESTMENT FOR ANY PARTICULAR INVESTOR. MOODY’S ISSUES ITS CREDIT RATINGS AND PUBLISHES MOODY’S PUBLICATIONS WITH THE EXPECTATION AND UNDERSTANDING THAT EACH INVESTOR WILL, WITH DUE CARE, MAKE ITS OWN STUDY AND EVALUATION OF EACH SECURITY THAT IS UNDER CONSIDERATION FOR PURCHASE, HOLDING, OR SALE.

MOODY’S CREDIT RATINGS AND MOODY’S PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS AND IT WOULD BE RECKLESS AND INAPPROPRIATE FOR RETAIL INVESTORS TO USE MOODY’S CREDIT RATINGS OR MOODY’S PUBLICATIONS WHEN MAKING AN INVESTMENT DECISION. IF IN DOUBT YOU SHOULD CONTACT YOUR FINANCIAL OR OTHER PROFESSIONAL ADVISER. ALL INFORMATION CONTAINED HEREIN IS PROTECTED BY LAW, INCLUDING BUT NOT LIMITED TO: COPYRIGHT LAW, AND NONE OF SUCH INFORMATION MAY BE COPIED OR OTHERWISE REPRODUCED, REPACKAGED, FURTHER TRANSMITTED, TRANSFERRED, DISSEMINATED, REDISTRIBUTED OR RESOLD, OR STORED FOR SUBSEQUENT USE FOR ANY SUCH PURPOSE, IN WHOLE OR IN PART, IN ANY FORM OR MANNER OR BY ANY MEANS WHATSOEVER, BY ANY PERSON WITHOUT MOODY’S PRIOR WRITTEN CONSENT.

All information contained herein is obtained by MOODY’S from sources believed by it to be accurate and reliable. Because of the possibility of human or mechanical error as well as other factors, however, all information contained herein is provided “AS IS” without warranty of any kind. MOODY’S adopts all necessary measures so that the information it uses in assigning a credit rating is of sufficient quality and from sources MOODY’S considers to be reliable including, when appropriate, independent third-party sources. However, MOODY’S is not an auditor and cannot in every instance independently verify or validate information received in the rating process or in preparing the Moody’s publications.

To the extent permitted by law, MOODY’S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim liability to any person or entity for any indirect, special, consequential, or incidental losses or damages whatsoever arising from or in connection with the information contained herein or the use of or inability to use any such information, even if MOODY’S or any of its directors, officers, employees, agents, representatives, licensors or suppliers, arising from or in connection with the information contained herein or the use of or inability to use any such information.

NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY SUCH RATING OR OTHER OPINION OR INFORMATION IS GIVEN OR MADE BY MOODY’S IN ANY FORM OR MANNER WHATSOEVER.

MOODY’S Investors Service, Inc., a wholly-owned credit rating agency subsidiary of Moody’s Corporation (“MCO”), hereby discloses that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by Moody’s Investors Service, Inc. have, prior to assignment of any rating, agreed to pay to Moody’s Investors Service, Inc. for appraisal and rating services rendered by it fees ranging from $1,500 to approximately $2,500,000. MCO and MIS also maintain policies and procedures to address the independence of MIS’s ratings and rating processes. Information regarding certain affiliations that may exist between directors of MCO and rated entities, and between entities that hold ratings from MIS and have also publicly reported to the SEC an ownership interest in MCO of more than 5%, is posted annually at www.moodys.com under the heading “Investor Relations — Corporate Governance — Director and Shareholder Affiliation Policy.”

Additional terms for Australia only: Any publication into this document is pursuant to the Australian Financial Services License of MOODY’S affiliate, Moody’s Investors Service Pty Limited ABN 61 003 399 657AFSL 336969 and/or Moody’s Analytics Australia Pty Limited ABN 94 105 136 972 AFSL 383569 (as applicable). This document is intended to be provided only to “wholesale clients” within the meaning of section 761G of the Corporations Act 2001. By continuing to access this document from within Australia, you represent to MOODY’S that you are, or are accessing the document as a representative of, a “wholesale client” and that neither you nor the entity you represent will directly or indirectly disseminate this document or its contents to “retail clients” within the meaning of section 761G of the Corporations Act 2001. MOODY’S credit rating is an opinion as to the creditworthiness of a debt obligation of the issuer, not on the equity securities of the issuer or any form of security that is available to retail investors. It would be reckless and inappropriate for retail investors to use MOODY’S credit ratings or publications when making an investment decision. If in doubt you should contact your financial or other professional adviser.

Additional terms for Japan only: Moody’s Japan K.K. (“MJJK”) is a wholly-owned credit rating agency subsidiary of Moody’s Group Japan K.K., which is wholly-owned by Moody’s Overseas Holdings Inc., a wholly-owned subsidiary of MCO. Moody’s K.K. (“MSFJ”) is a wholly-owned credit rating agency subsidiary of MJJK. MSFJ is not a NRSRO. Therefore, credit ratings assigned by MSFJ are Non-NRSRO Credit Ratings. Non-NRSRO Credit Ratings are assigned by an entity that is not a NRSRO and, consequently, the rated obligation will not qualify for certain types of treatment under U.S. laws. MJJK and MSFJ are credit rating agencies registered with the Japan Financial Services Agency and their registration numbers are FSA Commissioner (Ratings) No. 2 and 3 respectively.

MJJK or MSFJ (as applicable) hereby disclose that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by MJJK or MSFJ (as applicable) have, prior to assignment of any rating, agreed to pay to MJJK or MSFJ (as applicable) for appraisal and rating services rendered by it fees ranging from JP¥200,000 to approximately JP¥350,000,000. MJJK and MSFJ also maintain policies and procedures to address Japanese regulatory requirements.

REPORT NUMBER 1097211

4 December 2017
Not-for-profit and public healthcare - US: 2018 outlook changed to negative due to reimbursement and expense pressures
Not-for-profit and public healthcare - US: 2018 outlook changed to negative due to reimbursement and expense pressures.